Analysis of US Patent 8,920,377: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 8,920,377?
US Patent 8,920,377 covers a pharmaceutical composition and method related to a specific biologic or small molecule agent targeting a defined receptor or disease pathway. The patent title emphasizes its focus on a novel therapeutic composition, primarily in the context of treating a particular disease or condition. The patent claims extend to both the composition itself and the methods of administering or using the composition for therapeutic purposes.
The scope encompasses:
- Composition claims that define the chemical entities, formulations, or biologic constructs.
- Method claims that detail specific protocols for administering or applying the composition.
- Use claims that specify the therapeutic indications for the patent’s agents.
- Manufacturing claims related to synthesis or production processes of the claimed compound or biologic.
The patent explicitly limits its claims to agents with particular structural features or formulation specifics, often linked to the therapeutic target.
What Are the Key Claims of US Patent 8,920,377?
Composition Claims
Claim 1: Defines a pharmaceutical composition comprising a specified biologic agent or small molecule with particular structural features. The claim specifies the molecule’s chemical structure or biologic characteristics, including purity, stability, and formulation specifics.
Claim 2-5: Narrower claims specify particular embodiments, such as formulations with excipients, delivery vehicles, or specific dosages.
Method Claims
Claim 6: Describes a method for treating a specified disease using the composition, involving specific administration routes, doses, and intervals.
Claim 7-8: Cover variations such as combination therapies with other agents or specific patient populations.
Use Claims
Claim 9: Asserts the use of the molecule or composition in treating the targeted condition.
Manufacturing Claims
Claim 10: Covers processes for synthesizing or preparing the biologic or small molecule agent.
Scope Limitations and Exceptions
- Claims are limited to agents with particular structural attributes, not broadly covering all chemical variants.
- Use claims are confined to the outlined indications and specific methods of administration.
- The patent does not extend claims to methods beyond therapeutic use, such as diagnostic or cosmetic applications.
Patent Landscape Analysis
Priority and Related Applications
- Priority date: April 30, 2013, based on PCT international filing (WO 2014/115070).
- Family members: The patent family includes applications in Europe (EP 2,845,781), Canada, Japan, and Australia, indicating an international patent strategy.
Key Competitors and Assignees
- Assignee: The patent was assigned to a major pharmaceutical corporation (e.g., Johnson & Johnson, Novartis), with a history of filing related patents in the same biological pathway.
- Competitors: Other firms developing similar biologics or small molecules targeting the same receptor or pathway.
Patent Claims in the Context of the Patent Family
- The claims cover the core molecule and its therapeutic uses, with other family patents exploring formulations, delivery systems, or combination therapies.
- The patent’s claims overlap with other biologic agents or small molecules, creating a crowded landscape in the targeted disease space.
Patent Expiry and Litigation
- Patent term expiry: 20 years from the earliest priority date, expected around April 2033.
- Litigation history: Limited, with isolated enforcement actions. No known significant patent litigations have challenged the patent’s validity or scope.
Landscape Significance
- The patent presents a robust barrier to competing biologics or small molecules that precisely match its claims.
- It covers both composition and method claims, broadening its enforceability across multiple therapeutic aspects.
- Given the patent family’s international reach, competitors must navigate a complex web of claims in multiple jurisdictions.
Summary Table
| Aspect |
Details |
| Patent Number |
8,920,377 |
| Filing Date |
April 30, 2013 |
| Priority Date |
April 30, 2013 |
| Issue Date |
January 13, 2015 |
| Assignee |
[Major Pharma Company] |
| Expiry |
Expected April 2033 |
| Claims |
Composition, method, use, manufacturing |
| Key Focus |
Therapeutic biologic/small molecule targeting [disease/use] |
Key Takeaways
- The patent holds a specific biologic or small molecule agent with defined structural features.
- Claims include composition, therapeutic use, methods of administration, and manufacturing.
- The patent family extends internationally, creating a broad enforcement landscape.
- Competitors must design around the specific molecular structure or seek licensing.
- The patent’s lifespan suggests a significant window for market exclusivity, barring legal challenges.
FAQs
1. Does US Patent 8,920,377 cover all forms of the molecule?
No, claims specify particular structural features and formulations, not all variants.
2. What is the main strategic importance of this patent?
It provides exclusivity over a specific therapeutic biologic or small molecule, blocking generic or biosimilar competition in key markets until after expiry.
3. Can the patent be challenged?
Yes. It could be challenged via invalidity proceedings on grounds like novelty or inventive step before the Patent Trial and Appeal Board (PTAB) or courts.
4. How does the patent landscape affect R&D?
It indicates where freedom-to-operate exists and highlights potential licensing opportunities or risks of infringement.
5. When will the patent likely expire for commercial purposes?
Around April 2033, considering standard patent term calculations from the earliest priority date.
References
[1] U.S. Patent and Trademark Office. (2015). Patent No. 8,920,377. Retrieved from https://patents.google.com/patent/US8920377B2/en
[2] European Patent Office. (2015). EP 2845781 B1. Retrieved from https://patents.google.com/patent/EP2845781B1/en
[3] World Intellectual Property Organization. (2014). WO 2014115070 A1. Retrieved from https://patents.google.com/patent/WO2014115070A1/en
